267 related articles for article (PubMed ID: 37999735)
21. A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.
Kotecha RR; Doshi SD; Knezevic A; Chaim J; Chen Y; Jacobi R; Zucker M; Reznik E; McHugh D; Shah NJ; Feld E; Aggen DH; Rafelson W; Xiao H; Carlo MI; Feldman DR; Lee CH; Motzer RJ; Voss MH
Eur Urol Oncol; 2023 Nov; ():. PubMed ID: 37945488
[TBL] [Abstract][Full Text] [Related]
22. Microphthalmia family of transcription factors associated renal cell carcinoma.
Xie L; Zhang Y; Wu CL
Asian J Urol; 2019 Oct; 6(4):312-320. PubMed ID: 31768316
[TBL] [Abstract][Full Text] [Related]
23. TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.
Wang AX; Tian T; Liu LB; Yang F; He HY; Zhou LQ
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830782
[TBL] [Abstract][Full Text] [Related]
24. Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
Batavia AA; Rutishauser D; Sobottka B; Schraml P; Beerenwinkel N; Moch H
Mod Pathol; 2023 Aug; 36(8):100194. PubMed ID: 37088333
[TBL] [Abstract][Full Text] [Related]
25. What's new in the WHO 2022 classification of kidney tumours?
Alaghehbandan R; Siadat F; Trpkov K
Pathologica; 2022 Feb; 115(1):8-22. PubMed ID: 36645398
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas.
Seo AN; Yoon G; Ro JY
Adv Anat Pathol; 2017 Mar; 24(2):65-77. PubMed ID: 28181950
[TBL] [Abstract][Full Text] [Related]
27. Emerging Entities in Renal Neoplasia.
Mehra R; Smith SC; Divatia M; Amin MB
Surg Pathol Clin; 2015 Dec; 8(4):623-56. PubMed ID: 26612218
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemistry for the diagnosis of renal epithelial neoplasms.
Akgul M; Williamson SR
Semin Diagn Pathol; 2022 Jan; 39(1):1-16. PubMed ID: 34823973
[TBL] [Abstract][Full Text] [Related]
29. A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects.
Kuroda N; Sugawara E; Kusano H; Yuba Y; Yorita K; Takeuchi K
Pol J Pathol; 2018; 69(2):109-113. PubMed ID: 30351856
[TBL] [Abstract][Full Text] [Related]
30. ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y; Liu N; Guo W; Pu X; Guo H; Gan W; Li D
Pathol Res Pract; 2020 Dec; 216(12):153286. PubMed ID: 33197836
[TBL] [Abstract][Full Text] [Related]
31. TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma.
Wang XM; Zhang Y; Mannan R; Skala SL; Rangaswamy R; Chinnaiyan A; Su F; Cao X; Zelenka-Wang S; McMurry L; Xiao H; Spratt DE; Sangoi AR; Shao L; Betz BL; Brown N; Tickoo SK; McKenney JK; Argani P; Gupta S; Reuter VE; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Mod Pathol; 2021 Aug; 34(8):1596-1607. PubMed ID: 33854184
[TBL] [Abstract][Full Text] [Related]
32. Renal neoplasia with papillary architecture involving the pelvicalyceal system.
Gupta S; Cheville JC; Galeano BK; Sukov WR; Herrera-Hernandez L; Reed KA; Lohse CM; Thompson RH; Boorjian SA; Leibovich BC; Jimenez RE
Hum Pathol; 2021 Jan; 107():46-57. PubMed ID: 33166576
[TBL] [Abstract][Full Text] [Related]
33. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
[TBL] [Abstract][Full Text] [Related]
34. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.
Srigley JR; Delahunt B; Eble JN; Egevad L; Epstein JI; Grignon D; Hes O; Moch H; Montironi R; Tickoo SK; Zhou M; Argani P;
Am J Surg Pathol; 2013 Oct; 37(10):1469-89. PubMed ID: 24025519
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
[TBL] [Abstract][Full Text] [Related]
36. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract][Full Text] [Related]
37. A
Smith SC; Yu J; Paul AK
Int J Surg Pathol; 2024 May; 32(3):539-542. PubMed ID: 37415407
[TBL] [Abstract][Full Text] [Related]
38. TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma.
Lin J; Tang Z; Zhang C; Dong W; Liu Y; Huang H; Liu H; Huang J; Lin T; Chen X
Heliyon; 2023 May; 9(5):e16076. PubMed ID: 37215783
[TBL] [Abstract][Full Text] [Related]
39. Recent advances of immunohistochemistry for diagnosis of renal tumors.
Kuroda N; Tanaka A; Ohe C; Nagashima Y
Pathol Int; 2013 Aug; 63(8):381-90. PubMed ID: 23957913
[TBL] [Abstract][Full Text] [Related]
40. [SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts].
Agaimy A; Hartmann A
Pathologe; 2021 Nov; 42(6):571-577. PubMed ID: 34609565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
